Upcoming Stock Splits: The week of November 24 to November 28 will see several stock splits, including reverse splits from companies like Meihua International Medical Technologies, Mesa Air Group, BiomX Inc., and Lion Group Holding, aimed at maintaining compliance with exchange listing requirements.
Meihua International Medical Technologies: This China-based company will implement a 1-for-100 reverse share split effective November 24 to comply with Nasdaq's minimum bid-price requirement.
Mesa Air Group: The U.S. regional airline will execute a 15-for-1 reverse stock split on November 24 as part of its strategy to meet exchange listing standards ahead of a merger with Republic Airways Holdings.
BiomX Inc. and Lion Group Holding: BiomX will conduct a 1-for-19 reverse stock split on November 25 for compliance, while Lion Group will implement a 1-for-13 reverse ADS split on November 26 to meet listing requirements.
Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is 26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is 26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.950
Low
26.00
Averages
26.00
High
26.00
Current: 6.950
Low
26.00
Averages
26.00
High
26.00
H.C. Wainwright
Joseph Pantginis
Buy
upgrade
$15 -> $26
2025-11-25
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$15 -> $26
AI Analysis
2025-11-25
upgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis adjusted the firm's price target on BiomX to $26 from $15 and keeps a Buy rating on the shares. The adjusted target follows the company's reverse stock split.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$21 -> $15
2025-05-16
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$21 -> $15
2025-05-16
downgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on BiomX to $15 from $21 and keeps a Buy rating on the shares following the Q1 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHGE
Unlock Now
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2025-04-04
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2025-04-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$2 → $21
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$2 → $21
2025-04-01
Maintains
Strong Buy
Reason
About PHGE
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
